These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20499401)

  • 21. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
    Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
    Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Kantarjian H; O'Brien S; Jabbour E; Shan J; Ravandi F; Kadia T; Faderl S; Garcia-Manero G; Borthakur G; Cortes J
    J Clin Oncol; 2011 Aug; 29(23):3173-8. PubMed ID: 21747082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current therapy of chronic myeloid leukemia].
    Koskela H; Koskenvesa P; Mustjoki S; Porkka K
    Duodecim; 2012; 128(6):579-88. PubMed ID: 22506320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
    Garg RJ; Kantarjian H; O'Brien S; Quintás-Cardama A; Faderl S; Estrov Z; Cortes J
    Blood; 2009 Nov; 114(20):4361-8. PubMed ID: 19729517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
    Whiteley J; Iyer S; Candrilli SD; Kaye JA
    Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
    Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
    J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
    Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
    Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Mauro MJ
    Cancer Control; 2009 Apr; 16(2):108-21. PubMed ID: 19337197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
    Quintás-Cardama A; Cortes JE; O'Brien S; Ravandi F; Borthakur G; Liu D; Bleickardt E; Chen TT; Kantarjian HM
    Cancer; 2009 Jul; 115(13):2912-21. PubMed ID: 19402171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
    Aoki J; Ohashi K; Kobayashi T; Kakihana K; Hirashima Y; Sakamaki H
    Leuk Lymphoma; 2012 Jul; 53(7):1412-4. PubMed ID: 22168276
    [No Abstract]   [Full Text] [Related]  

  • 37. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
    Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
    Radich JP
    Cancer; 2012 Jan; 118(2):300-11. PubMed ID: 21717440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
    Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
    J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
    Kantarjian H; Cortes J
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.